PerkinElmer will collaborate with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China, the company announced in a press release. The two organizations will share knowledge, expertise, and innovative capabilities to establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients.
The program will include sequencing patient samples in order to establish genomic information for drug profiling, including validation of biomarkers for personalized disease treatment and related informatics solutions. As a part of this program, PerkinElmer and NCDS will first undertake a study on metabolic diseases to validate new diagnostics for the Chinese populations through utilizing next-generation sequencing technologies. Once optimized, the technology platform will be implemented in testing laboratories and hospitals throughout China.
NCDS is a joint program of China’s Ministry of Science and Technology, the Chinese Academy of Sciences, and the Shanghai municipality government. At present, it is the only national center specializing in screening for new drugs. As a public technology platform, the Center offers drug-screening services and technical consultation to universities, research institutions, and pharmaceutical companies in China.